ETOP 29-25 START-lung: A multicentre phase II trial of tarlatamab in patients with pretreated extensive-stage small cell lung cancer (ES-SCLC) and ECOG PS 2.
This research study, called START-lung, is looking at a new treatment called tarlatamab for patients in the UK who have extensive-stage (advanced) small cell lung cancer that has previously been treated. We are focusing on patients who might be a bit frailer due to their illness (ECOG PS 2). The main goal is to understand how many patients are still alive after 12 months of treatment. We will also be looking at how much the cancer shrinks, how long the benefits last, control of the disease, and how long people live without their cancer getting worse. Importantly, we'll be carefully checking for any side effects and how serious they might be.
At a glance
What is this study about?
This clinical trial is designed to investigate a new medicine named tarlatamab. It's for people in the UK who have a type of lung cancer called small cell lung cancer, which has spread widely (extensive-stage) and has already been treated with other medicines. Sometimes, after initial treatments, the cancer can come back or continue to grow, and new options are needed.
The specific group of patients this study is focusing on are those who are managing their daily activities but might feel a bit weaker or tire more easily than completely fit individuals. This is often referred to as their 'ECOG PS' score, and a score of 2 means they can still look after themselves but can't do heavy work and spend some time in bed during the day. Exploring new treatments for this group is very important.
The main thing the researchers want to find out is how many people taking tarlatamab are still alive after 12 months. They will also be tracking other important aspects, such as whether the cancer shrinks, how long these good effects last, how well the medicine controls the cancer, and how long people live without their cancer growing. Of course, safety is a top priority, so they'll be closely monitoring any side effects that might occur.
Key takeaways
- This study is testing a promising new medicine called tarlatamab for advanced small cell lung cancer.
- It's for people whose cancer has already been treated and who might feel a bit weaker but are still generally independent.
- The main aim is to see if tarlatamab helps people live longer and to understand its effects on the cancer.
- Safety is a priority, and researchers will carefully track any side effects.
- This is a Phase II study, meaning we are learning more about the drug's effectiveness and safety in a focused patient group.
Who may be eligible?
This study is looking for adult patients who are 18 years old or older. Both men and women can take part.
You would need to have specific type of lung cancer called extensive-stage small cell lung cancer, which means it has spread quite a bit, and you would have already received some treatment for it.
Also, your overall health and how well you can do daily tasks would need to fit a certain level, indicating that while you might be a bit weaker or more tired than usual, you are generally able to care for yourself.
Could this study suit you?
Answer these quick questions to see if you may be eligible. This is a guide only — the research team makes the final call.
- Are you 18 years old or older?
- Do you have extensive-stage small cell lung cancer?
- Have you already received treatment for your lung cancer?
- Do you feel capable of caring for yourself, even if you get tired or feel a bit weaker than usual?
What does participation involve?
If you decide to take part in this study, you would receive the new medicine, tarlatamab. This is a "Phase II" study, which means we are trying to understand more about how well the treatment works and what its side effects are, in a focused group of people. You would have regular visits to the hospital or clinic for treatment and check-ups. During these visits, the doctors and nurses would monitor your health, do tests to see how the cancer is responding, and ask about any side effects you might be experiencing. The total length of your participation would depend on how your cancer responds to the treatment and your overall health, and you would be followed up regularly.
Potential risks and benefits
Locations (4)
- —UnverifiedFrance
- —UnverifiedGreece
- —UnverifiedSpain
- —UnverifiedItaly
Common questions
What is tarlatamab?
Tarlatamab is a new investigational medicine being tested to treat a type of lung cancer.
What does extensive-stage small cell lung cancer mean?
It means the small cell lung cancer has spread beyond the main area where it started to other parts of the body.
What does 'pretreated' mean?
It means you have already received some treatment for your lung cancer, and doctors are now looking for another option.
What are 'side effects'?
Side effects are unwanted reactions or problems that can occur as a result of taking a medicine or receiving a treatment.
Can I stop participating in the study if I want to?
Yes, you can choose to leave the study at any time, for any reason, and it won't affect your ongoing medical care.
How to find out more
Always speak to your GP or specialist before deciding to take part in a study.
Discussion
Community discussion
Powered by our forum at community.patient.info. Please be respectful — this is not medical advice.